A single injection reduced moderate-to-severe hot flashes by 83 percent over four weeks in a mid-stage trial, compared with 33 percent for placebo, in the first efficacy readout for an antibody approach to a symptom that affects most women going through menopause.
AbCellera reported Phase 2 results for ABCL635, an investigational neurokinin-3 receptor antagonist antibody, in an announcement this week. In absolute terms, treated participants averaged 8.8 fewer moderate-to-severe episodes per day at week four, compared with 3.5 fewer on placebo. In terms of severity, the drug produced a 58 percent reduction compared to 12 percent for placebo. The company also reported statistically significant improvements in sleep and in patients' own assessment of their overall condition.
